Core Viewpoint - UnitedHealth is the world's largest health insurance company, pursuing a unique M&A strategy to consolidate the healthcare benefit market and expand its data analytics business, with a 'Strong Buy' rating and a one-year target price of $700 per share [1][11] M&A Strategy and Market Position - Over the past three years, UnitedHealth has spent more than $36 billion on acquisitions, including the $13 billion acquisition of Change Healthcare, which enhanced its competitive advantage and boosted Optum Insight revenue by nearly 30% in FY23 [2] - The acquisition of Change Healthcare has improved UnitedHealth's overall margin profile, with Optum Insight delivering an operating margin of 22.5% compared to the group's overall margin of 8.7% [2] - UnitedHealth's total backlog reached $33 billion, growing by 3% year-over-year, driven by business process and IT services for health systems [2] - The $5.4 billion acquisition of LHC Group in February 2023 allows UnitedHealth to expand its home and community-based care services [2] Cyberattack Impact - A major cyberattack in February led to a shutdown of systems for over a week, with a ransom payment of $22 million made to the hacker [3] - The incident is expected to reduce overall EPS for FY24 by $1.90 to $2.05, with additional financial costs anticipated from penalties and increased capital expenditure for IT upgrades [3][4] - The company has provided over $9 billion in advance funding and loans to affected care providers [3] Financial Performance and Growth Outlook - UnitedHealth reported a 6.4% year-on-year revenue increase in Q2 FY24, driven by strong expansion in Optum and UnitedHealthcare [5] - The divestiture of the Brazilian business resulted in a quarterly EPS impact of -$1.28, but the decision is viewed favorably due to exposure to FX risk [6] - The U.S. healthcare spending is projected to grow by 7.5% in 2023, providing a solid foundation for UnitedHealth's growth [6][7] - The company is expected to deliver 6% organic revenue growth, with acquisitions contributing an additional 2% to topline growth [7] DCF Valuation - UnitedHealth is estimated to deliver 8% revenue growth in the near future, with operating margins expected to expand by 10 basis points annually [8] - The calculated cost of equity is 9.4%, leading to a one-year target price of $700 per share based on discounted cash flow analysis [9]

Core Viewpoint - UnitedHealth Group has experienced significant stock price appreciation and revenue growth, driven primarily by its Optum segment, but faces challenges from rising medical costs and market performance compared to the S&P 500 [1][4][5]. Financial Performance - UnitedHealth stock has increased by 80% since January 2021, rising from $335 to approximately $600, while the S&P 500 rose about 45% during the same period [1]. - The company's revenue grew by 48%, from $257 billion in 2020 to $381 billion currently, with a P/S ratio increase of 18% to 1.4x [1]. - Revenue has risen at an average annual growth rate of 13% from $257 billion in 2020 to $367 billion in 2023, with OptumHealth's revenue growing by 67% in the same timeframe [4]. Segment Analysis - The Optum segment has been a key driver of growth, attributed to increased demand for healthcare services and value-based arrangements [4]. - UnitedHealth's insurance business has faced challenges due to rising medical costs, leading to an increase in the medical care ratio from 82% in 2022 to 84.7% in mid-2024 [5]. Valuation and Earnings - The current valuation of UnitedHealth stock is estimated at $580 per share, based on a 21x P/E multiple and expected earnings of $27.55 per share for 2024 [3]. - The operating margin has contracted from 8.2% in 2020 to 7.3% recently, influenced by rising medical costs and a cyberattack [6]. - Earnings per share increased from $16.03 in 2020 to $23.86 in 2023, with expectations for 2024 earnings in the range of $27.50 to $28.00 [6]. Market Position and Outlook - Despite consistent value growth over the past three years, UnitedHealth has underperformed the S&P 500 in 2023, with returns of only 1% compared to the S&P's 24% [2]. - The company is projected to deliver mid-single-digit average annual top-line growth over the next three years, but higher medical costs pose a near-term risk [7].

Core Viewpoint - UnitedHealth Group (UNH) is viewed as a solid buy-and-hold investment, with recent earnings growth outpacing stock price increases, making it attractive for long-term investors despite facing challenges in 2024 [1][10]. Financial Performance - UNH has a market capitalization of nearly $550 billion and has recently reached an all-time high in share price [1]. - The company reported adjusted EPS impacts from a cyberattack on its Change Healthcare subsidiary, estimated to reduce EPS by $0.60 to $0.70, representing about 2.35% of EPS expectations for fiscal 2024 [2]. - Earnings growth for fiscal years 2022 and 2023 was 16.67% and 13.20%, respectively, with EPS estimates of $21.85 and $24.90 [4][5]. - Analysts expect continued double-digit earnings growth over the next two years, even accounting for the cyberattack's impact [5]. Dividend Growth - UNH has increased its dividend for 15 consecutive years, with a recent increase from $1.88 to $2.10 per quarter, reflecting an 11.7% growth [7]. - The dividend payout ratio based on next year's EPS estimates is 30%, indicating solid coverage, although free cash flow (FCF) per share is currently concerning at $6.72, leading to a 125% FCF dividend payout [8]. - The company expects FCF per share to rebound next year, potentially reaching $27 to $30 or more [8]. Insider Activity - There has been significant insider selling, with over $560 million in stock sold in the last five years compared to only $1.5 million in purchases, raising concerns about management confidence [2][3]. - Despite this, insider selling can occur for various reasons, and it does not necessarily indicate negative sentiment [3]. Market Position - UNH is considered a defensive stock, likely to perform better in a volatile market, although it has faced downward pressure from broader market trends [6]. - The forward P/E multiple is approximately 21.5x, aligning with the current market multiple, suggesting that UNH is trading around its fair value [5][6]. Conclusion - Despite facing challenges in the first half of 2024, including a cyberattack and antitrust review, UNH's growth trajectory remains intact, making it a viable option for dividend growth investors [10].

Company Performance - UnitedHealth Group (UNH) closed at $594.10, showing a -0.47% change from the previous session, underperforming the S&P 500 which gained 1.16% [1] - Over the past month, UNH shares appreciated by 6.82%, outperforming the Medical sector's gain of 4.5% and the S&P 500's gain of 3.48% [1] - The upcoming earnings disclosure is expected to report an EPS of $7.05, reflecting a 7.47% increase year-over-year, with projected revenue of $99.19 billion, a 7.39% rise from the same quarter last year [1] Full-Year Estimates - Zacks Consensus Estimates forecast earnings of $27.69 per share and revenue of $398.84 billion for the full year, indicating year-over-year changes of +10.23% and +7.32% respectively [2] - Recent revisions to analyst forecasts for UnitedHealth Group are crucial as they often reflect short-term business dynamics, with positive revisions indicating a favorable business outlook [2] Valuation Metrics - UnitedHealth Group has a Forward P/E ratio of 21.56, which is a premium compared to the industry's average Forward P/E of 16.31 [3] - The PEG ratio for UNH is currently 1.66, compared to the industry average PEG ratio of 1.4 [3] Industry Ranking - The Medical - HMOs industry, part of the Medical sector, has a Zacks Industry Rank of 212, placing it in the bottom 17% of all industries [4] - The Zacks Industry Rank evaluates the performance of industry groups, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [4]

Core Viewpoint - UnitedHealth Group is presented as a strong dividend stock with significant growth potential, making it an attractive long-term investment option for dividend investors [1]. Group 1: Dividend Growth - UnitedHealth has a strong track record of increasing its dividends over the past 14 years, prioritizing dividend growth with substantial increases in recent years, resulting in nearly double the dividend income for investors over the last five years [2]. - The current dividend yield of 1.4% is considered average due to a 27% appreciation in stock price over the past year, but long-term investors will benefit from both the dividend and stock price growth [3]. Group 2: Financial Strength - UnitedHealth has sound financials with a manageable payout ratio of just over 50%, indicating minimal risk of not paying or increasing its dividend, despite a $7 billion charge from the sale of its Brazilian operations [4]. - The company reported revenue of $368 billion, a nearly 30% increase from $285 billion in 2021, and profits rose from $17 billion to over $22 billion during the same period, showcasing its growth capabilities [5]. Group 3: Growth Strategy - UnitedHealth actively pursues acquisitions to diversify its business and enhance growth prospects, including the acquisition of LHC Group and the pending acquisition of Amedisys, which are expected to contribute to earnings growth of 13% to 16% per year [6]. - The company's strategy of expanding its services, particularly in the Medicare sector, positions it well for continued growth, which could lead to more dividend increases in the future [6]. Group 4: Valuation - UnitedHealth is considered a top dividend and growth stock, trading at a forward price-to-earnings multiple of 21, slightly lower than the average of 22 for the Health Care Select Sector SPDR Fund, making it a compelling buy for long-term investors [7].

Core Viewpoint - Brokerage recommendations, particularly for UnitedHealth Group (UNH), suggest a strong buy sentiment, but reliance solely on these recommendations may not be advisable due to potential biases from brokerage firms [1][2]. Group 1: Brokerage Recommendations - UnitedHealth has an average brokerage recommendation (ABR) of 1.06, indicating a consensus between Strong Buy and Buy, with 92% of recommendations being Strong Buy and 8% being Buy [1]. - Despite the positive ABR, studies indicate that brokerage recommendations often fail to guide investors effectively towards stocks with high price appreciation potential [2][5]. - The vested interests of brokerage firms can lead to a bias in their analysts' ratings, resulting in a disproportionate number of favorable ratings compared to negative ones [2][5]. Group 2: Zacks Rank vs. ABR - Zacks Rank is a proprietary stock rating tool that categorizes stocks based on earnings estimate revisions, providing a more reliable indicator of near-term stock performance compared to ABR [3][4]. - The Zacks Rank is based on quantitative models and is updated more frequently, reflecting timely changes in earnings estimates, while ABR may not always be current [6]. - UnitedHealth currently holds a Zacks Rank of 3 (Hold), indicating a cautious outlook despite the favorable ABR [7]. Group 3: Earnings Estimates - The Zacks Consensus Estimate for UnitedHealth's earnings for the current year remains unchanged at $27.69, suggesting stability in analysts' views on the company's earnings prospects [7]. - The unchanged consensus estimate, along with other factors, contributes to the Zacks Rank of 3, indicating that the stock may perform in line with the broader market in the near term [7].

Core Insights - The Zacks Focus List is a curated portfolio of 50 stocks expected to outperform the market over the next 12 months, serving as a starting point for long-term investors [2] - The Focus List has demonstrated strong past performance, gaining 13.85% in 2020 compared to the S&P 500's 9.38%, and a cumulative return of 2,519.23% since February 1, 1996, against the S&P's 854.95% [3] Focus List Methodology - Stocks are selected for the Focus List based on earnings estimate revisions, which are critical for predicting future growth and profitability [4] - The Zacks Rank, a proprietary stock-rating model, utilizes changes in quarterly earnings expectations to help investors build a winning portfolio, categorizing stocks into five groups from "Strong Buy" to "Strong Sell" [5] Spotlight on UnitedHealth Group - UnitedHealth Group has seen a significant increase of 387.93% in share price since being added to the Focus List at $120.33, now priced at $587.13 [6] - Recent upward revisions in earnings estimates for fiscal 2024 have led to a consensus estimate increase of $0.12 to $27.69, with expected earnings growth of 10.2% for the current fiscal year [6]

Core Viewpoint - UnitedHealth Group Incorporated (UNH) is solidifying its position in the healthcare sector, with a notable stock performance and optimistic growth prospects driven by rising healthcare spending and strategic diversification [1][2][3]. Group 1: Stock Performance and Market Position - UNH shares have increased by 15.1% over the past three months, outperforming the industry growth of 12.2% and the S&P 500's growth of 5.9% [1]. - The current stock price is $584.51, just 1.2% below its 52-week high, indicating strong investor confidence [1]. - The stock is trading above its 50-day and 200-day moving averages, suggesting robust upward momentum [1]. Group 2: Growth Drivers - Rising healthcare spending and increasing disease cases are expected to continue, positioning UNH to capitalize on this demand despite lower-than-expected margins from private Medicare plans [2]. - Anticipated growth in Medicaid membership could provide a significant tailwind for the company [2]. - The divestiture in Brazil is expected to have minimal short-term impact but may enhance long-term profitability by allowing UNH to focus on more lucrative operations [2]. Group 3: Strategic Initiatives - UNH is diversifying its portfolio by expanding into home healthcare and analytics, aiming to enhance partner value and create future opportunities [3]. - The company is focusing on AI and advanced tools to scale its business, achieve long-term cost reductions, and improve efficiency [3]. - Strong cash flow supports strategic acquisitions and shareholder value initiatives, with $6.7 billion returned to shareholders in the first half of 2024 through buybacks and dividends [3]. Group 4: Financial Outlook - UNH projects adjusted net EPS for 2024 in the range of $27.50 to $28.00, reflecting a 10.5% increase from the 2023 figure of $25.12 [4]. - The Zacks Consensus Estimate for 2024 adjusted earnings is $27.69 per share, indicating a 10.2% year-over-year growth [5]. - Revenue estimates for 2024 and 2025 suggest year-over-year growth of 7.3% and 8.2%, respectively [5]. Group 5: Challenges and Risks - U.S. regulators upheld 2025 rates for private Medicare plans, which may lower profitability for UNH and other health insurers [6]. - The medical care ratio for UNH averaged 83.2% in 2023 and increased to 85.1% in Q2 2024, indicating potential profitability challenges [7]. - A cyber-attack earlier this year is estimated to have cost UNH around $1.6 billion and has led to increased scrutiny and potential regulatory investigations [7]. Group 6: Valuation - UNH is trading at a forward price/earnings ratio of 19.50X, higher than its five-year median of 18.96X and the industry average of 16.97X, indicating a premium valuation [8].

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?The Zac ...

Core Insights - The Zacks Focus List is a curated portfolio of 50 stocks aimed at long-term investors, expected to outperform the market over the next 12 months [2] - The Focus List has demonstrated strong past performance, with a cumulative return of 2,519.23% from February 1, 1996, to March 31, 2021, compared to the S&P 500's return of 854.95% [3] Focus List Methodology - Stocks are selected for the Focus List based on earnings estimate revisions, which are critical for predicting future growth and profitability [4] - The Zacks Rank, a proprietary stock-rating model, utilizes changes in quarterly earnings expectations to help investors build a successful portfolio [5] - The Focus List primarily includes stocks rated as 1 (Strong Buy) or 2 (Buy), indicating a positive earnings consensus among analysts [5] Spotlight on UnitedHealth Group - UnitedHealth Group, added to the Focus List on June 22, 2015, has seen its share price increase by 381.68% from $120.33 to $579.61 [6] - Recent upward revisions in earnings estimates for UnitedHealth Group indicate a consensus estimate increase of $0.12 to $27.69 for fiscal 2024, with a forecasted earnings growth of 10.2% for the current fiscal year [6]